Thrombotic microangiopathy in acute prostatitis
DOI:
https://doi.org/10.32818/reccmi.a9n1a8Keywords:
prostatitis, thrombocytopenia, thrombotic microangiopathy, eculizumab, plasmapheresisAbstract
We present the case of a 46-year-old man who was admitted to the hospital for an episode of acute prostatitis and who, during hospitalization, presented a progressive and severe deterioration of renal function accompanied by hemolytic anemia and severe thrombocytopenia. After an etiological study, a diagnosis of thrombotic microangiopathy was reached. Treatment with eculizumab and plasmapheresis was started with a good response.
Downloads
Metrics
References
Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60(3): 831-846. doi: https://doi.org/10.1046/j.1523-1755.2001.060003831.x (último acceso mar. 2024). DOI: https://doi.org/10.1046/j.1523-1755.2001.060003831.x
Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347(8): 589-600. doi: https://doi.org/10.1056/nejmra020528 (último acceso mar. 2024). DOI: https://doi.org/10.1056/NEJMra020528
Little DJ, Mathias LM, Page EE, Kremer Hovinga JA, Vesely SK, George JN. Long-term kidney outcomes in patients with acquired thrombotic thrombocytopenic purpura. Kidney Int Rep. 2017; 2(6): 1088-1095. doi: https://doi.org/10.1016/j.ekir.2017.06.007 (último acceso mar. 2024). DOI: https://doi.org/10.1016/j.ekir.2017.06.007
Jokiranta TS. HUS and atypical HUS. Blood. 2017; 129(21): 2847-2856. doi: https://doi.org/10.1182/blood-2016-11-709865 (último acceso mar. 2024). DOI: https://doi.org/10.1182/blood-2016-11-709865
Hanna RM, Henriksen K, Kalantar-Zadeh K, Ferrey A, Burwick R, Jhaveri KD. Thrombotic microangiopathy syndromes-common ground and distinct frontiers. Adv Chronic Kidney Dis. 2022; 29(2):149-160.e1. Accesible en: https://escholarship.org/content/qt4rp9q4pd/qt4rp9q4pd.pdf (último acceso mar. 2024). DOI: https://doi.org/10.1053/j.ackd.2021.11.006
Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH et al. Atypical aHUS: state of the art. Mol Immunol. 2015; 67(1): 31-42. doi: https://doi.org/10.1016/j.molimm.2015.03.246 (último acceso mar. 2024). DOI: https://doi.org/10.1016/j.molimm.2015.03.246
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8(4): 554-562. doi: https://doi.org/10.2215/CJN.04760512 (último acceso mar. 2024). DOI: https://doi.org/10.2215/CJN.04760512
Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C. Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol. 2014; 29(5): 841-851. doi: https://doi.org/10.1007/s00467-013-2654-x (último acceso mar. 2024). DOI: https://doi.org/10.1007/s00467-013-2654-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Arturo Muñoz-Blanco, Beatriz Pérez-Monte Mínguez, Rebeca Fuerte-Martínez, José Luis Valle-López, Jorge Francisco Gómez-Cerezo
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
